Table 3.
Incidence of herpes zoster reported in the included RCTs, LTEs and RWS
| Disease | JAKi | Dose | RCTs | LTEs | RWS | |||
|---|---|---|---|---|---|---|---|---|
| Cumulative incidence % [weeks¥] | IR/ER* (/100 PY) | Cumulative incidence % [weeks¥] | IR/ER (/100 PY) | Cumulative incidence % [weeks¥] | IR/ER (/100 PY) | |||
| RA | TOFA | 5 mg BID | 0–7.5% [12–96] 12.4% [192§] | – | 10.7% [456] | 2.2–7.1 | 1.3–16.7% [24–81.6§] | 1.3–6.5 |
| UPA | 0.5–7.4% [12–48] | 2.3*–3.1* | 6.1–21.9% [84–108] | 3.1–12.3 | – | – | ||
| BARI | 2 mg QD | 0–1.7% [12–24] | – | – | – | 1.3–6.2% [24–48] (2 or 4 mg QD) | 8.4 (2 or 4 mg QD) | |
| 4 mg QD | 1.3–2.3% [12–28] 7% [50] | – | 1.3–5.6% [52] | 1.3–5.8 | ||||
| PsA | TOFA | 5 mg BID | 0–3.3% [12–48] | – | 2.5% [144] | 1.7 | – | – |
| UPA | 15 mg QD | 0.9–1.4% [24] | 3.8* | – | – | – | – | |
| AS | TOFA | 5 mg BID | 0–2.3% [16–48] | – | – | – | – | – |
| UPA | 15 mg QD | 2.5% [64] | 2.1* | – | – | – | – | |
| UC | TOFA | 5 mg BID | 1.4–1.5% [24–52] | 1.3 | 4.5–7.4% [48–180] | 2.1–2.3 | 0–7.9% [24–60§] (5 or 10 mg BID) | – |
| 10 mg BID | 0.5–5.1% [8–52] | 3.2 | 7.8–12.3% [48–180] | 3.6–7.6 | – | |||
| UPA | 15 mg QD | 0% [8] | – | – | – | – | – | |
| 30 mg QD | 0% [8] | – | – | – | – | – | ||
| 45 mg QD | 0.8% [8] | – | – | – | – | – | ||
¥Observational period
§Mean/median
RCT randomized controlled trial, LTEs long-term extension studies, RWS real-world study, RA rheumatoid arthritis, PsA psoriatic arthritis, AS ankylosing spondylitis, UC ulcerative colitis, TOFA tofacitinib, BARI baricitinib, UPA upadacitinib, BID twice daily, QD once daily, IR incidence rate, ER event rate, PY patient-years
*ER/100 PY